The EFNB1 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the Jurkat human T lymphocyte cell line. This heterogeneous product contains a mixture of cells with EFNB1 gene disruptions, providing a robust loss-of-function model while avoiding clonal bias. It is suited for functional assays where genetic diversity is advantageous.
The parental Jurkat cell line (clone E6-1) originates from human acute T cell leukemia and is a canonical model for investigating T cell receptor (TCR) signaling, apoptosis, and activation. These suspension cells maintain key signaling pathways, including MAPK/ERK and PI3K/Akt, and are widely used in immunology and oncology research. Their genetic tractability and well-defined background facilitate CRISPR-based gene editing.
EFNB1 (ephrin-B1) is a transmembrane ligand that engages EphB receptor tyrosine kinases to mediate bidirectional signaling, controlling cell adhesion, migration, and axon guidance. In T cells, EFNB1 reverse signaling activates Src family kinases and focal adhesion kinase (FAK), triggering Rho GTPases (RhoA, Rac1) and downstream effectors such as ERK1/2 and Akt. EFNB1 interacts with EphB1?CB4 receptors and PDZ-domain adaptors (GRIP1, syntenin, PDZ-RGS3), and its expression is regulated by TCR/CD28 costimulation, NF-??B, and AP-1. Disruption of EFNB1 abrogates EphB-mediated bidirectional signaling, impairing Src/FAK and Rho GTPase cascades, which leads to altered T cell adhesion, migration, and activation responses.
In the Jurkat T cell context, EFNB1 knockout enables systematic dissection of ephrin-mediated regulation of lymphocyte adhesion, motility, and immune signaling. This model is particularly relevant for studying the role of Eph/ephrin pathways in leukemic cell dissemination and for evaluating their contribution to tumor?Cimmune interactions. Moreover, EFNB1 is associated with cancer metastasis in multiple solid tumors and with developmental disorders such as craniofrontonasal syndrome, highlighting the translational value of this knockout model.
These EFNB1 Knockout Jurkat Polyclonal Cells support a variety of research applications, including analysis of T cell adhesion and migration, mechanistic studies of Eph/ephrin signaling in leukemia, and screening of pathway-specific inhibitors. Compatible assays include Western blotting for EFNB1 and phospho-signaling, RT-qPCR, transwell migration and adhesion assays, flow cytometry for T cell markers and phospho-ERK, co-culture with EphB-Fc, and RNA-seq. For additional information, please contact Ascent Research.
